The Experts below are selected from a list of 78783 Experts worldwide ranked by ideXlab platform
Vassilis A Georgoulias - One of the best experts on this subject based on the ideXlab platform.
-
A retrospective analysis of Second-Line Chemotherapy or best supportive care in patients with advanced-stage non-small-cell lung cancer.
Clinical lung cancer, 2006Co-Authors: Dora Hatzidaki, Sofia Agelaki, Dimitris Mavroudis, Ioannis G. Vlachonikolis, Athanasios Alegakis, Vassilis A GeorgouliasAbstract:Abstract Background We retrospectively evaluated the clinical characteristics and outcome of patients with stage IIIB/IV non–small-cell lung cancer (NSCLC) enrolled in first-line Chemotherapy trials conducted by our group with respect to receiving or not receiving subsequent treatment. Patients and Methods Data were collected from 634 patients with stage IIIB/IV NSCLC treated with platinum and nonplatinum agent–based firstline regimens. Patient survival was calculated from the day of registration to first-line Chemotherapy trials (OS1) as well as from the day of first-line treatment failure or the initiation of Second-Line Chemotherapy (OS2) until death. The decision for administering Second-Line Chemotherapy was, in all cases, at the discretion of the physician. Two hundred twenty-four patients (35.3%) received Second-Line Chemotherapy (Second-Line group) in the context of Second-Line clinical trials run by the same group, and 410 (64.7%) received best supportive care (BSC group). There were significant differences between Second-Line and BSC groups in terms of age, histology, early discontinuation of first-line Chemotherapy, and performance status after first-line treatment. Results Three (1.3%) complete and 25 (11.2%) partial responses to Second-Line Chemotherapy were observed for an overall response rate of 12.5% (95% confidence interval, 8.2%–16.8%). The median OS1 was 13 months and 7 months ( P P Conclusion The Second-Line Chemotherapy and BSC groups represent different populations of patients with NSCLC. Factors indicative of increased probability of survival could be used to identify the subgroup of patients most likely to benefit from Second-Line Chemotherapy.
-
Second-Line Chemotherapy in relapsing or refractory patients with non-small cell lung cancer.
Lung cancer (Amsterdam Netherlands), 2002Co-Authors: Vassilis A GeorgouliasAbstract:A comprehensive review of the literature on the efficacy of antitumor agents either alone or in combination as Second-Line Chemotherapy in advanced non-small cell lung cancer (NSCLC) cancer was undertaken. An increasing number of patients with advanced NSCLC who progress or fail to respond to front-line Chemotherapy are young and in good performance status, requiring further treatment. Since advanced NSCLC is an incurable and fatal disease, the aims of Second-Line Chemotherapy should be the palliation of the symptoms and, probably, the improvement of survival. Docetaxel, gemcitabine, irinotecan and paclitaxel have shown a promising activity as Second-Line treatment in patients with NSCLC, and several phase II studies of regimens associating either these drugs or these drugs with CDDP and ifosfamide have shown objective responses ranging from 15 to 25% and a median survival ranging from 4 to 8 months. Two randomized trials have clearly demonstrated that single agent docetaxel in the second line setting confers a survival benefit and an improvement of both the quality of life and the control of tumor-related symptoms establishing, thus, the role of docetaxel as standard treatment for relapsing or refractory patients with NSCLC. Increasing evidence from both phase II and III studies seems to indicate that Second-Line Chemotherapy may confer a survival benefit in a selected group of patients with advanced NSCLC. Copyright 2002 Elsevier Science Ireland Ltd.
-
Second-Line Chemotherapy in relapsing or refractory patients with non-small cell lung cancer.
Lung Cancer, 2002Co-Authors: Vassilis A GeorgouliasAbstract:Purpose: A comprehensive review of the literature on the efficacy of antitumor agents either alone or in combination as Second-Line Chemotherapy in advanced non-small cell lung cancer (NSCLC) cancer was undertaken. Results: An increasing number of patients with advanced NSCLC who progress or fail to respond to front-line Chemotherapy are young and in good performance status, requiring further treatment. Since advanced NSCLC is an incurable and fatal disease, the aims of Second-Line Chemotherapy should be the palliation of the symptoms and, probably, the improvement of survival. Docetaxel, gemcitabine, irinotecan and paclitaxel have shown a promising activity as Second-Line treatment in patients with NSCLC, and several phase II studies of regimens associating either these drugs or these drugs with CDDP and ifosfamide have shown objective responses ranging from 15 to 25% and a median survival ranging from 4 to 8 months. Two randomized trials have clearly demonstrated that single agent docetaxel in the second line setting confers a survival benefit and an improvement of both the quality of life and the control of tumor-related symptoms establishing, thus, the role of docetaxel as standard treatment for relapsing or refractory patients with NSCLC. Conclusions: Increasing evidence from both phase II and III studies seems to indicate that Second-Line Chemotherapy may confer a survival benefit in a selected group of patients with advanced NSCLC.
K. Zarogoulidis - One of the best experts on this subject based on the ideXlab platform.
-
The role of Second-Line Chemotherapy in small cell lung cancer: a retrospective analysis
OncoTargets and therapy, 2013Co-Authors: K. Zarogoulidis, Efimia Boutsikou, Paul Zarogoulidis, Kostas Porpodis, Dimitris Latsios, Kaid Darwiche, Lutz Freitag, Theodoros Kontakiotis, Haidong HuangAbstract:BACKGROUND: To evaluate the benefit of Second-Line Chemotherapy with platinum-based treatment in patients with recurrent small cell lung cancer (SCLC). PATIENTS AND METHODS: A total of 535 patients continued with follow-up or best supportive care if needed, and 229 patients who progressed after the completion of first-line Chemotherapy were treated with Second-Line Chemotherapy at the time of progression. In total, 103/229 patients received paclitaxel 190 mg/m(2) and carboplatin 5.5 area under the curve while 126/229 patients received etoposide 200 mg/m(2) and carboplatin 5.5 area under the curve every 28 days. RESULTS: Patients administered Second-Line Chemotherapy lived significantly longer, with a median survival of 422 days compared to 228 days in patients with best supportive care alone (P
-
The role of second line Chemotherapy in small cell lung cancer: A retrospective analysis
European Respiratory Journal, 2013Co-Authors: Efimia Boutsikou, Paul Zarogoulidis, Kostas Porpodis, Dimitris Latsios, Maria Kipourou, K. ZarogoulidisAbstract:PURPOSE: To evaluate the benefit of second line Chemotherapy with platinum based treatment in patients with recurrent small cell lung cancer (SCLC). PATIENTS AND METHODS: 764 patients first diagnosed with SCLC received first-line platinum based Chemotherapy for a maximum of six cycles. 535 patients continued with follow up or best supportive care (BSC) if needed and 229 patients who progressed after the completion of first line Chemotherapy were treated with second line Chemotherapy at the time of progression: 103/229 patients received paclitaxel 190mg/m2 and carboplatin 5.5AUC(PC) while 126/229 patients received etoposide 200 mg/m2 and carboplatin 5.5 AUC(EC) every 28 days. RESULTS: Patients administered Second-Line Chemotherapy lived significantly longer with median survival 422 days compared to 228 days in patients with BSC only (P CONCLUSION: Patients administered new generation Second-Line Chemotherapy had significantly longer survival than patients administered BSC. Continuation with carboplatin/paclitaxel or carboplatin/etoposide as second line Chemotherapy has no significant survival impact and did not improve responses rates. Sensitivity to front line treatment is a prognostic factor to OS in SCLC patients.
-
AB 41. The role of second line Chemotherapy in small cell lung cancer
Journal of Thoracic Disease, 2012Co-Authors: Efimia Boutsikou, Paul Zarogoulidis, Kostas Porpodis, Dimitris Latsios, Maria Kipourou, K. ZarogoulidisAbstract:Background To evaluate the benefit of second line Chemotherapy with platinum based treatment in patients with recurrent small cell lung cancer (SCLC).
J Montesinos - One of the best experts on this subject based on the ideXlab platform.
-
The Cochrane Library - Second‐line Chemotherapy for non‐small cell lung cancer
The Cochrane database of systematic reviews, 2002Co-Authors: Xavier Bonfill Cosp, C Serra, M Sacristán, M Nogué, F Losa, J MontesinosAbstract:Background The role of Second-Line Chemotherapy for the treatment of patients with non-small cell lung cancer (NSCLC) who have relapsed or failed to respond to first-line treatment was unclear. Objectives To determine the effectiveness of any Second-Line Chemotherapy in patients with NSCLC. Search methods Medline (1966-July 2001), Embase (1974-July 2001), Cancerlit (1993-July) and tthe Cochrane Central Register of Controlled Trials (CENTRAL, issue 2 2001) were searched. In addition a handsearch was performed and experts in the field contacted to identify any further studies that had not been found by the electronic searches. Selection criteria Randomised controlled clinical trials in which any Second-Line Chemotherapy was compared with placebo or best supportive care in patients with NSCLC who had failed to respond to any previous Chemotherapy regimen. Data collection and analysis Data were extracted by 2 independent authors and revised by a third author. Main results Only one study was included. This study included a total of 204 patients who were randomised to receive either doxetaxel or best supportive care. Following an unacceptably high toxic death rate the dose of doxetaxel was reduced from 100 mg/m² to 75 mg/m². Docetaxel gave an extra 2.4 months survival - an average of 7.0 months vs 4.6 months on best supportive care. At 1 year after diagnosis 29% of doxetaxel treated patients were alive compared with 19% of the best supportive care group. Authors' conclusions Definitive recommendations cannot be made since evidence is only available from one randomised controlled trial which, though of reasonable quality had a number of limitations. There is currently no evidence to support Second-Line treatment of patients with poor performance status. Larger, well-designed controlled trials are needed to further evaluate whether the benefits of Second-Line Chemotherapy to patients with non-small cell lung cancer outweigh its risks and costs.
-
Second-Line Chemotherapy for non-small cell lung cancer.
The Cochrane database of systematic reviews, 2001Co-Authors: X Bonfill, C Serra, M Sacristán, M Nogué, F Losa, J MontesinosAbstract:The role of Second-Line Chemotherapy for the treatment of patients with non-small cell lung cancer (NSCLC) who have relapsed or failed to respond to first-line treatment was unclear. To determine the effectiveness of any Second-Line Chemotherapy in patients with NSCLC. Bibliographic databases were searched. Handsearching and contact with experts was also performed. Randomised controlled clinical trials in which any Second-Line Chemotherapy was compared with BSC in patients with NSCLC who had previously failed to any previous Chemotherapy regimen. Data was extracted by 2 independent reviewers and revised by all authors. Only one study was included. It randomised 204 patients to receive either doxetaxel or BSC. Following an unacceptably high toxic death rate the dose of doxetaxel was reduced from 100 mg/m(2) to 75 mg/m(2). Doxetaxel gave an extra 2.4 months of survival - an average of 7.0 months vs 4.6 months on BSC. At 1 year after diagnosis 29% of doxetaxel treated patients were alive compared with 19% of the BSC group. Definitive recommendations cannot be made since evidence is only available from one randomised controlled trial which, though of reasonable quality, had a number of limitations. There is currently no evidence to support Second-Line treatment of patients with poor performance status. Larger, well-designed controlled trials are needed to further evaluate whether the benefits of Second-Line Chemotherapy to patients with NSCLC outweigh its risks and costs.
Efimia Boutsikou - One of the best experts on this subject based on the ideXlab platform.
-
The role of Second-Line Chemotherapy in small cell lung cancer: a retrospective analysis
OncoTargets and therapy, 2013Co-Authors: K. Zarogoulidis, Efimia Boutsikou, Paul Zarogoulidis, Kostas Porpodis, Dimitris Latsios, Kaid Darwiche, Lutz Freitag, Theodoros Kontakiotis, Haidong HuangAbstract:BACKGROUND: To evaluate the benefit of Second-Line Chemotherapy with platinum-based treatment in patients with recurrent small cell lung cancer (SCLC). PATIENTS AND METHODS: A total of 535 patients continued with follow-up or best supportive care if needed, and 229 patients who progressed after the completion of first-line Chemotherapy were treated with Second-Line Chemotherapy at the time of progression. In total, 103/229 patients received paclitaxel 190 mg/m(2) and carboplatin 5.5 area under the curve while 126/229 patients received etoposide 200 mg/m(2) and carboplatin 5.5 area under the curve every 28 days. RESULTS: Patients administered Second-Line Chemotherapy lived significantly longer, with a median survival of 422 days compared to 228 days in patients with best supportive care alone (P
-
The role of second line Chemotherapy in small cell lung cancer: A retrospective analysis
European Respiratory Journal, 2013Co-Authors: Efimia Boutsikou, Paul Zarogoulidis, Kostas Porpodis, Dimitris Latsios, Maria Kipourou, K. ZarogoulidisAbstract:PURPOSE: To evaluate the benefit of second line Chemotherapy with platinum based treatment in patients with recurrent small cell lung cancer (SCLC). PATIENTS AND METHODS: 764 patients first diagnosed with SCLC received first-line platinum based Chemotherapy for a maximum of six cycles. 535 patients continued with follow up or best supportive care (BSC) if needed and 229 patients who progressed after the completion of first line Chemotherapy were treated with second line Chemotherapy at the time of progression: 103/229 patients received paclitaxel 190mg/m2 and carboplatin 5.5AUC(PC) while 126/229 patients received etoposide 200 mg/m2 and carboplatin 5.5 AUC(EC) every 28 days. RESULTS: Patients administered Second-Line Chemotherapy lived significantly longer with median survival 422 days compared to 228 days in patients with BSC only (P CONCLUSION: Patients administered new generation Second-Line Chemotherapy had significantly longer survival than patients administered BSC. Continuation with carboplatin/paclitaxel or carboplatin/etoposide as second line Chemotherapy has no significant survival impact and did not improve responses rates. Sensitivity to front line treatment is a prognostic factor to OS in SCLC patients.
-
AB 41. The role of second line Chemotherapy in small cell lung cancer
Journal of Thoracic Disease, 2012Co-Authors: Efimia Boutsikou, Paul Zarogoulidis, Kostas Porpodis, Dimitris Latsios, Maria Kipourou, K. ZarogoulidisAbstract:Background To evaluate the benefit of second line Chemotherapy with platinum based treatment in patients with recurrent small cell lung cancer (SCLC).
Caterina Vivaldi - One of the best experts on this subject based on the ideXlab platform.
-
multivariate prognostic factors analysis for second line Chemotherapy in advanced biliary tract cancer
British Journal of Cancer, 2014Co-Authors: Lorenzo Fornaro, Sergio Di Girolamo, Michele Milella, S Cereda, Nicola Silvestris, Donatella Santini, Giuseppe Aprile, Sara Lonardi, Francesco Leone, Caterina VivaldiAbstract:Multivariate prognostic factors analysis for Second-Line Chemotherapy in advanced biliary tract cancer
-
Multivariate prognostic factors analysis for Second-Line Chemotherapy in advanced biliary tract cancer
British Journal of Cancer, 2014Co-Authors: Lorenzo Fornaro, Sergio Di Girolamo, Michele Milella, S Cereda, Nicola Silvestris, Donatella Santini, Giuseppe Aprile, Sara Lonardi, Francesco Leone, Caterina VivaldiAbstract:Background: The role of Second-Line Chemotherapy (CT) is not established in advanced biliary tract cancer (aBTC). We investigated the outcome of aBTC patients treated with Second-Line CT and devised a prognostic model. Methods: Baseline clinical and laboratory data of 300 consecutive aBTC patients were collected and association with overall survival (OS) was investigated by multivariable Cox models. Results: The following parameters resulted independently associated with longer OS: Eastern Cooperative Oncology Group performance status of 0 ( P
